// The platform

Let your data guide your decisions
and your expertise call the shots.

ACT 01. CONTEXT

Start anywhere.
Stay in your stack.

●  altrovia · trial setup
› _
// context 0 / 4 read
▼ Understood

↳

▸ Ready to proceed Pressure-test the design against precedent Continue →
ACT 02. ACTION

Optimize your design.
Across dimensions.

Optimization · candidate Phase 2
▸ starting
audit — parameters —
APPLY CHANGES
ACT 03. SIMULATION

See the trial
before it runs.

Simulation · candidate Phase 2
▴ 12 prior commands 3 sims queued
› simulatebaseline
⟁fitting recruitment model from 14 priors
⟁cross-referencing SUSTAIN-1, PIONEER-3, AWARD-7
✓10,000 trajectories · P(success) 84.0%
✓DB lock · week 52
› addinterimfutility@ wk 26cp < 0.20
⟁computing operating characteristics under H1
✓early-stop probability 12% at IA1
⚠power 84% → 82% (−2 pp)
✓DB lock 52 → 48 wks · cost −$800k
› re-estimateNatIA1
⟁solving for N under observed variance (cap +12.5%)
✓N 320 → 360 · power +7 pp
⚠+6 weeks · cost +$1.4M
› enrichHbA1c≥8.5%
⟁resampling within enriched stratum (n_screen ×2.4)
✓N 320 → 240 (enriched stratum)
⚠label restricted to enriched subgroup
✓−6 wks · −$1.2M · power +4 pp
› combine futility + adaptive N + ...
↑recall tabcomplete ⌘kclear
// live preview
active scenario 01 · baseline scenario 02 · interim futility scenario 03 · adaptive N scenario 04 · enrichment baseline · no change −4w · −$800k · −2pp +6w · +$1.4M · +7pp −6w · −$1.2M · +4pp
APPLY SCENARIO
ACT 04. ASSEMBLY

Bring it all together.
Keep everyone in sync.

Draft · §2.1 · 3 collaborators
active · room open
// section 2.1 · study objectives

Primary endpoint

v2.3 · drafting

Primary. To evaluate the efficacy of semaglutide 1.0 mg once-weekly versus placebo (matching placebo subcutaneous injection)[3] in reducing HbA1c from baseline to Week 52 in adults with type 2 diabetes inadequately controlled on stable metformin (≥ 1500 mg/day).

Secondary. To evaluate change in body weight, fasting plasma glucose, and the proportion of subjects achieving HbA1c < 7.0% at Week 52, consistent with the ADA 2026 general glycaemic target.[7]

Exploratory. To explore associations between baseline HbA1c, BMI, and treatment response; to characterise PK–PD relationships in a subpopulation of N≈120 across two academic centres.

7 / 10 sections drafted 2 open comments 11 diffs accepted 21 citations linked